慢性腎臟病藥物市場：按藥物類別、給藥途徑、患者類型、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2030 年

慢性腎病是一種腎功能在多年內逐漸衰退的疾病。慢性腎臟病也稱為慢性腎病。隨著腎臟疾病的惡化，大量廢物積聚在血液中。與慢性腎病相關的其他問題包括高血壓、紅細胞計數低、骨骼脆弱、營養不良和神經病。

引起慢性腎病的主要原因包括糖尿病、高血壓、慢性腎小球腎炎、慢性腎盂腎炎、長期服用抗炎藥、自身免疫性疾病、多囊腎、阿爾波特病、先天性畸形、腎病急性期延長等。

市場動態

市場上的主要參與者正專注於獲得監管批准，預計這將在預測期內推動市場增長。例如，2020 年 9 月，專注於開發一流藥物以改善腎臟和心血管疾病患者治療的生物製藥公司 Arderix 宣布，接受透析治療的慢性腎病 (CKD) 成人患者宣布美國食品藥品監督管理局 (U.S. Food)和藥物管理局 (FDA) 已接受替那帕醇用於控制血清磷的新藥申請 (NDA)

政府機構為提高認識所做的努力、慢性腎病患病率的增加以及產品的推出正在推動全球慢性腎病藥物市場的增長。例如，美國疾病控制與預防中心在 2021 年發表的一篇文章估計，超過七分之一的人，即 15% 的美國成年人，即 3700 萬人患有慢性腎病。根據同一消息來源，與 18-44 歲的人群相比，慢性腎病在 45-64 歲的人群 (12%) 和 65 歲以上的人群 (38%) 中更為常見。

這項研究的主要特點

• 本報告對全球慢性腎臟病藥物市場進行了深入分析，顯示了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。I在這裡。
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 我們還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
• 根據公司亮點、產品組合、主要亮點、績效和策略等參數介紹全球慢性腎病治療市場主要參與者的概況。
• 本研究涵蓋的主要公司包括賽諾菲、阿斯利康公司、安進公司、再生元製藥公司、艾伯維公司、ProKidney 公司、輝瑞公司、拜耳公司、F. Hoffmann-La Roche AG、Kissei Pharmaceutical Co., Ltd.、Reata Pharmaceuticals, Inc.、GlaxoSmithKline plc.、Ardelyx, Inc.、Boehringer Ingelheim International GmbH、Novo Nordisk A/S、Novartis AG、Johnson & Johnson、Astellas Pharma Inc.、Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc. , Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals 和 KBP Biosciences Co. ., 有限公司
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
• 本報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球慢性腎病治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按藥物類別
  • 按給藥途徑劃分的市場概況
  • 市場概況：按患者類型分類
  • 市場概況：按分銷渠道
  • 市場概況：按地區
• 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 監管情景
• 主要亮點
• 研究與開發
• 聯合研究、併購方案
• 主要發展
• 最近的產品批准和發布
• 害蟲分析
• 管道分析
• 流行病學

第 4 章全球慢性腎臟病藥物市場-冠狀病毒 (COVID-19) 大流行的影響

• COVID-19 對市場的影響
• 對全球慢性腎病藥物市場的影響
• 對臨床試驗的影響

第 5 章。全球慢性腎臟病藥物市場：按藥物類別分類，2017-2030

• ACE 抑製劑
• 血管緊張素受體阻滯劑 (ARB)
• B 受體阻滯劑
• 鈣拮抗劑
• 袢利尿劑
• 紅細胞生成促進劑 (ESA)
• 磷酸鹽結合劑
• 其他

第 6 章。全球慢性腎臟病藥物市場：按給藥途徑，2017-2030

• 口服給藥
• 皮下給藥
• 靜脈給藥

第 7 章。全球慢性腎病藥物市場：按患者類型分列，2017-2030

• 人工透析
• 其他

第 8 章。全球慢性腎臟病藥物市場：分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 9 章。全球慢性腎臟病藥物市場：地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第10章競爭格局

• 熱圖分析
• 公司簡介
  • Sanofi
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD.
  • Akebia Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

第 11 章章節

• 參考資料
• 調查方法

Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.

The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.

Market Dynamics

Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.

Key features of the study:

• This report provides an in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market.

Detailed Segmentation:

• Global Chronic Kidney Disease Drugs Market, By Drug Class:
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• Global Chronic Kidney Disease Drugs Market, By Route of Administration:
  • Oral
  • Subcutaneous
  • Intravenous
• Global Chronic Kidney Disease Drugs Market, By Patient Type:
  • Dialysis
  • Others
• Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Chronic Kidney Disease Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Sanofi*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD
  • Akebia Therapeutics, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route Of Administration
  • Market Snapshot, By Patient Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Regulatory Scenario
• Key Highlights
• Research and Development
• Collaboration, Mergers, and Acquisitions Scenario
• Key Development
• Recent Product Approvals and Launches
• PEST Analysis
• Pipeline Analysis
• Epidemiology

4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Impact on the market
• Impact on Global Chronic Kidney Disease Drugs Market
• Impact on Clinical Trials

5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• ACE Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Angiotensin Receptor Blockers (ARBs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• B-Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Loop Diuretics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Phosphate Binders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Dialysis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Sanofi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD.
  • Akebia Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

11. Section

• References
• Research Methodology
• About Us and Sales Contact